
LDRE
DXNDN
DXD
LDRE
DXNDN
DXD
XDXE
DVNE
DXD
LDRE
DXNDN
C
DXD
C CC
EC1
EC2
EC3
EC4
EC5
TM
CP1
CP2
β
α
ACT
HAV
PM
MF

Fig. 1

human N-cad	DWVIPPINLPENSRGPFPQELVRIRSDRDKNLSLRYSVTGPGADQPPTGIFILNPISGQLSVTKPLDREQ	IARFHLRAHAVDINGNQVENPIDIVINVIDMNDNRPEF
mouse N-cad	DWVIPPINLPENSRGPFPQELVRIRSDRDKNLSLRYSVTGPGADQPPTGIFIINPISGQLSVTKPLDREL	IARFHLRAHAVDINGNQVENPIDIVINVIDMNDNRPEF
cow N-cad	DWVIPPINLPENSRGPFPQELVRIRSDRDKNLSLRYSVTGPGADQPPTGIFIINPISGQLSVTKPLDREL	IARFHLRAHAVDINGNQVENPIDIVINVIDMNDNRPEF
human P-cad	DWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREE	IAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKF
mouse P-cad	EWVMPPIFVPENGKGPFPQRLNQLKSNKDRGTKIFYSITGPGADSPPEGVFTIEKESGWLLLHMPLDREK	IVKYELYGHAVSENGASVEEPMNISIIVTDQNDNKPKF
human E-cad	DWVIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRER	IATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEF
mouse E-cad	DWVIPPISCPENEKGEFPKNLVQIKSNRDKETKVFYSITGQGADKPPVGVFIIERETGWLKVTQPLDREA	IAKYILYSHAVSSNGEAVEDPMEIVITVTDQNDNRPEF

Fig. 2



N-Ac-CHAVC-NH_2



N-Ac-CHGVC-NH_2



H-CHAVC-NH_2



H-CHGVC-NH_2



N-Ac-KHAVD-NH_2



N-Ac-KHGVD-NH_2

Fig. 3A



#28

N-Ac-DHAVK-NH_2



#29

N-Ac-DHGVK-NH_2



#30

N-Ac-KHAVE-NH_2



#31

N-Ac-KHGVE-NH_2



#32

N-Ac-CVAHC-NH_2



#33

N-Ac-CVGHC-NH_2

Fig. 3B



#49

H-KHAVD-NH_2



#50

H-KHGVD-NH_2



#10

N-Ac-CHAVDC-NH_2



#11

N-Ac-CHGVDC-NH_2



#12

N-Ac-CAHAVC-NH_2



#13

N-Ac-CAHGVC-NH_2

Fig. 3C



#14

N-Ac-CAHAVDIC-NH_2



#15

N-Ac-CAHGVDIC-NH_2



#22

N-Ac-CAHAVDC-NH_2



#23

N-Ac-CAHGVDC-NH_2



#78

N-Ac-CRAHAVDC-NH_2



#79

N-Ac-CRAHGVDC-NH_2

Fig. 3D



#80

N-Ac-CLRAHAVC-NH_2



#81

N-Ac-CLRAHGVC-NH_2



#82

N-Ac-CLRAHAVDC-NH_2



#83

N-Ac-CLRAHGVDC-NH_2

Fig. 3E



#38

AHAVDI



#39

AHGVDI



#49

H-KHAVD-NH_2



#50

H-KHGVD-NH_2



#45

H-CAHAVDC-NH_2



#46

H-CAHGVDC-NH_2

Fig. 3F



#47

H-CAHAVDIC-NH_2



#48

H-CAHGVDIC-NH_2



#16

N-Ac-CSHAVC-NH_2



#17

N-Ac-CSHGVC-NH_2



#18

N-Ac-CHAVSC-NH_2



#19

N-Ac-CHGVSC-NH_2

Fig. 3G



#20

N-Ac-CSHAVSC-NH_2



#21

N-Ac-CSHGVSC-NH_2



#24

N-Ac-CSHAVSSC-NH_2



#25

N-Ac-CSHGVSSC-NH_2



#66

N-Ac-CHAVSSC-NH_2



#67

N-Ac-CHGVSSC-NH_2

Fig. 3H



#68

SHAVSS



#69

SHGVSS



#70

N-Ac-KSHAVSSD-NH_2



#71

N-Ac-KSHGVSSD-NH_2

Fig. 3I


60
50
40
30
20
10
0
Mean neurite length, μm
No peptide
Peptide 1,500 μg/ml
3T3
NCAM
L1
N-cadherin

Fig. 4



Fig. 5A



Fig. 5B



Fig. 5C

Fig. 6A



Fig. 6B



Fig. 6C

Fig. 7A

Fig. 7B



Fig. 7C

Fig. 8A

Fig. 8B

Fig. 8C



Fig. 9A



Fig. 9B



Fig. 9C



Fig. 9D



Fig. 9E



Fig. 9F



Fig. 10A



Fig. 10B



Fig. 11A



Fig. 11B



Fig. 11C



Fig. 11D

Fig. 12A



Fig. 12B



Fig. 12C

Fig. 12D



Fig. 13A



Fig. 13B



Fig. 13C



Fig. 14A



Fig. 14B



Fig. 15A



Fig. 15B


CONCENTRATION OF OREGON GREEN IN RECEIVER
COMPARISON BETWEEN TREATMENT AND CONTROL
CELL MEAN FOR CONCENTRATION (mcg/5mL)
1.6
0.8
0
6
12
24
36
48
HOURS
TREATMENT
CONTROL

Fig. 16


CONCENTRATION OF RHODAMINE GREEN IN RECEIVER
COMPARISON BETWEEN TREATMENT AND CONTROL
CELL MEAN FOR CONCENTRATION (mcg/5mL)
120
60
0
6
12
24
36
48
HOURS
TREATMENT
CONTROL

Fig. 17


CONCENTRATION OF OREGON GREEN FOUND IN THE RECEIVER
COMPARISON BETWEEN TREATMENT AND CONTROL
CELL MEAN FOR CONCENTRATION (mcg/5mL)
120
60
0
6
12
24
36
48
HOURS
TREATMENT
CONTROL

Fig. 18


CONCENTRATION OF RHODAMINE GREEN FOUND IN THE RECEIVER
COMPARISON BETWEEN TREATMENT AND CONTROL
CELL MEAN FOR CONCENTRATION (mcg/5mL)
30
15
0
6
12
24
36
48
HOURS
TREATMENT
CONTROL

Fig. 19


CHRONIC TOXICITY
ON THE EXTERNAL COMPOUND #2
MEAN OF BODY WEIGHT (g)
30
28
26
24
22
20
0
1
2
3
4
5
6
7
8
9
DAYS
SALINE 0.9% i.p.
125 mg/Kg i.p.
20 mg/Kg i.p.
2 mg/Kg i.p.

Fig. 20


STABILITY IN MOUSE WHOLE BLOODS FOR CANCER (2)
% REMAINING
120
60
0
0
50
100
150
200
250
TIME(min.)

Fig. 21


60
50
40
30
20
10
0
Mean neurite length, μm
3T3
N-CAD
N-CAD
+ pep 1
N-CAD
+ pep 3

Fig. 22


Inhibition of neurite outgrowth by N-Ac-CHAVC-NH2
% inhibition of neurite outgrowth
80
60
40
20
0
-20
0.5
0.1
0.2
0.3
0.4
0.5
Peptide concentration (mM)
3T3 cells + Ncad
3T3 alone

Fig. 23



Fig. 24


Inhibition of neurite outgrowth by N-Ac-CHAVDC-NH2
% inhibition of neurite outgrowth
100
80
60
40
20
0
0.0
0.1
0.2
0.3
0.4
Peptide concentration (mM)

Fig. 25


Inhibition of neurite outgrowth by N-Ac-CHAVDIC-NH2
% inhibition of neurite outgrowth
120
100
80
60
40
20
0
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
Peptide concentration (mM)

Fig. 26


Inhibition of neurite outgrowth by N-Ac-CHAVDINC-NH2
% inhibition of neurite outgrowth
100
80
60
40
20
0
-20
0.00
0.05
0.10
0.15
0.20
0.25
0.30
Peptide concentration (mM)

Fig. 27

Fig. 28A



Fig. 28B


SKOV3 Tumors in Nude Mice
Relative Tumor Volume Change (%)
100
75
50
25
0
ADH1
PBS
0
1
2
3
4
5
Days

Fig. 29

ADH1 (2mg/kg) killed after 5 days

Fig. 30A



Fig. 30B

ADH1 (2mg/kg) killed after 5 days



Fig. 31



Fig. 32

Fig. 33

Fig. 34

Fig. 35B



Fig. 35D

Fig. 35A

Fig. 35C


24 Hours
48 Hours
% Dead Cells
100
75
50
25
0
Control
Ad1
Ad3
0.5 mg/mL
Ad1
Ad3
0.25 mg/mL

Fig. 36

Control



Fig. 37A

ADH148 1mg/ml



Fig. 37B



Fig. 38A

Fig. 38B



Fig. 38C



Fig. 38D



Fig. 38E



Fig. 38F



Fig. 38G

Fig. 38H

Fig. 39A

Fig. 39B



Fig. 39C



Fig. 39D



Fig. 39E



Fig. 39F



Fig. 39G



Fig. 39H



Fig. 40B

Fig. 40A



Fig. 40D



Fig. 40C



Fig. 40F

Fig. 40E


Exherin (2 mg/kg)
Exherin (0.2 mg/kg)
Saline alone
Relative Change in Tumor Volume (%)
75
50
25
0
-25
0
1
2
3
4
5
Days

Fig. 41



Fig. 42A



Fig. 42B


Mean Tumor Volume
(mm3)
350
300
250
200
150
100
50
0
15
20
25
30
35
40
45
Day

Fig. 43


Inhibition of neurite outgrowth with N-cadherin specific CAR sequence mimics (250ug/mL)
% Inhibition of neurite outgrowth
120
100
80
60
40
20
0
N-Ac-CAHAVC-NH2
N-Ac-CHAVC-NH2
N-Ac-CHAVDC-NH2
N-Ac-CAHAVDIC-NH2
N-Ac-LRAHAVDC-NH2

Fig. 44



FIG. 45A



FIG. 45B



FIG. 46A



FIG. 46B



FIG. 46C



FIG. 47A



FIG. 47B